ArticleFrontiers in medicine2026
Carbapenem-resistant
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective study aimed to identify the clinical features and prognostic determinants in intensive care unit (ICU) patients with carbapenem-resistant Methods: This retrospective cohort study included 185 ICU patients with CRAB-BSI at a tertiary care hospital between 2013 and 2023. Based on 30-day outcomes, patients were categorized into survival and non-survival groups. Independent risk factors for mortality were identified through univariate and multivariate logistic regression analyses. These factors were used to construct a nomogram prediction model. Model performance was evaluated by assessing discrimination using the area under the receiver operating characteristic curve with a calibration plot, and clinical utility via decision curve analysis. Results: The 30-day mortality rate among ICU patients with CRAB-BSI was 60.0%. Multivariate analysis revealed that age [odds ratio (OR) = 1.04, 95% confidence interval (CI): 1.02-1.07], impaired consciousness (OR = 5.10, 95% CI: 2.27-11.45), prior corticosteroid use (OR = 5.82, 95% CI: 2.10-16.12), Sequential Organ Failure Assessment (SOFA) score (OR = 1.26, 95% CI: 1.12-1.42), and C-reactive protein (CRP) level (OR = 1.01, 95% CI: 1.01-1.02) were independent risk factors for 30-day mortality. A nomogram incorporating these variables achieved an area under the curve (AUROC) of 0.863 for predicting 30-day mortality risk. The calibration curve indicated excellent concordance between predictions and observed outcomes, and decision curve analysis demonstrated significant clinical net benefit over a wide range of probability thresholds. Conclusion: Mortality is high in ICU patients with CRAB-BSI and is significantly associated with age, impaired consciousness, corticosteroid use, SOFA score, and CRP level. The developed nomogram exhibits strong predictive accuracy and may function as a practical tool for quantitative management decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.